Adjuvant Chemotherapy Superior to Toripalimab in Resected Mucosal Melanoma
Source: Cancer Therapy Advisor, June 2023
Chemotherapy is more effective than toripalimab as adjuvant therapy in patients with resected mucosal melanoma, according to research presented at the ASCO Annual Meeting 2023.
Patients who received chemotherapy, consisting of temozolomide and cisplatin, had better recurrence-free survival (RFS), distant metastasis-free survival (DMFS), and overall survival (OS) outcomes than patients who received toripalimab, researchers found.
The researchers conducted this retrospective study in 247 patients with resected mucosal melanoma. The patients had received temozolomide plus cisplatin (n=169) or toripalimab (n=78) as adjuvant therapy between 2013 and 2019.